Benchmark Reaffirms Hold Rating for AbCellera Biologics (NASDAQ:ABCL)
AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “hold” rating reissued by stock analysts at Benchmark in a research report issued on Monday,Benzinga reports. ABCL has been the subject of a number of other reports. KeyCorp reduced their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” […]
AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “hold” rating reissued by stock analysts at Benchmark in a research report issued on Monday,Benzinga reports. ABCL has been the subject of a number of other reports. KeyCorp reduced their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” […]
